EIGRQ
Price
$8.50
Change
-$0.00 (-0.00%)
Updated
Sep 27 closing price
KMSTF
Price
$6.40
Change
-$0.00 (-0.00%)
Updated
Mar 12 closing price
Ad is loading...

EIGRQ vs KMSTF

Header iconEIGRQ vs KMSTF Comparison
Open Charts EIGRQ vs KMSTFBanner chart's image
Eiger BioPharmaceuticals
Price$8.50
Change-$0.00 (-0.00%)
Volume$1.59K
CapitalizationN/A
KADIMASTEM
Price$6.40
Change-$0.00 (-0.00%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
EIGRQ vs KMSTF Comparison Chart
Loading...
VS
EIGRQ vs. KMSTF commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EIGRQ is a Hold and KMSTF is a Hold.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (EIGRQ: $8.50 vs. KMSTF: $6.40)
Brand notoriety: EIGRQ and KMSTF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EIGRQ: 27% vs. KMSTF: 100%
Market capitalization -- EIGRQ: $12.59M vs. KMSTF: $8.58M
EIGRQ [@Biotechnology] is valued at $12.59M. KMSTF’s [@Biotechnology] market capitalization is $8.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EIGRQ’s FA Score shows that 1 FA rating(s) are green whileKMSTF’s FA Score has 0 green FA rating(s).

  • EIGRQ’s FA Score: 1 green, 4 red.
  • KMSTF’s FA Score: 0 green, 5 red.
According to our system of comparison, EIGRQ is a better buy in the long-term than KMSTF.

Price Growth

EIGRQ (@Biotechnology) experienced а 0.00% price change this week, while KMSTF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

EIGRQ is expected to report earnings on Mar 14, 2024.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
EIGRQ($12.6M) has a higher market cap than KMSTF($8.58M). EIGRQ YTD gains are higher at: 26.206 vs. KMSTF (-1.477). KMSTF has higher annual earnings (EBITDA): -9.53M vs. EIGRQ (-68.74M). EIGRQ has higher revenues than KMSTF: EIGRQ (15.8M) vs KMSTF (0).
EIGRQKMSTFEIGRQ / KMSTF
Capitalization12.6M8.58M147%
EBITDA-68.74M-9.53M721%
Gain YTD26.206-1.477-1,774%
P/E RatioN/AN/A-
Revenue15.8M0-
Total Cash2.13MN/A-
Total Debt41.2MN/A-
FUNDAMENTALS RATINGS
EIGRQ: Fundamental Ratings
EIGRQ
OUTLOOK RATING
1..100
49
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

EIGRQ and

Correlation & Price change

A.I.dvisor indicates that over the last year, EIGRQ has been loosely correlated with ATBPF. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if EIGRQ jumps, then ATBPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EIGRQ
1D Price
Change %
EIGRQ100%
N/A
ATBPF - EIGRQ
48%
Loosely correlated
N/A
IRON - EIGRQ
42%
Loosely correlated
+0.73%
KMSTF - EIGRQ
41%
Loosely correlated
N/A
SRZN - EIGRQ
35%
Loosely correlated
-1.87%
MOLN - EIGRQ
28%
Poorly correlated
N/A
More

KMSTF and

Correlation & Price change

A.I.dvisor indicates that over the last year, KMSTF has been loosely correlated with IRON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KMSTF jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMSTF
1D Price
Change %
KMSTF100%
N/A
IRON - KMSTF
53%
Loosely correlated
+0.73%
ATBPF - KMSTF
50%
Loosely correlated
N/A
EIGRQ - KMSTF
41%
Loosely correlated
N/A
ZVRA - KMSTF
30%
Poorly correlated
+0.95%
ACUT - KMSTF
28%
Poorly correlated
N/A
More